Q3 Earnings Estimate for TRAX Issued By HC Wainwright

First Tracks Biotherapeutics (NASDAQ:TRAX) – Investment analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of First Tracks Biotherapeutics in a report released on Thursday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.96) per share for the quarter, down from their prior estimate of ($0.90). HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for First Tracks Biotherapeutics’ current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for First Tracks Biotherapeutics’ Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.83) EPS, FY2028 earnings at ($3.84) EPS, FY2029 earnings at ($2.80) EPS and FY2030 earnings at ($2.17) EPS.

TRAX has been the topic of several other research reports. Zacks Research raised shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th. Barclays boosted their price objective on First Tracks Biotherapeutics from $48.00 to $65.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Wedbush increased their price objective on First Tracks Biotherapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Piper Sandler raised their target price on First Tracks Biotherapeutics from $54.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Wolfe Research started coverage on First Tracks Biotherapeutics in a research report on Tuesday. They set an “outperform” rating and a $83.00 target price on the stock. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.00.

First Tracks Biotherapeutics Trading Up 0.6%

NASDAQ:TRAX opened at $43.88 on Monday. First Tracks Biotherapeutics has a one year low of $14.72 and a one year high of $49.91. The company has a market capitalization of $1.57 billion and a P/E ratio of -23.85. The stock’s 50-day simple moving average is $31.51.

First Tracks Biotherapeutics (NASDAQ:TRAX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.21).

First Tracks Biotherapeutics Company Profile

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.